Summary
Patent 9,913,910 covers novel formulations and methods connected to a specific therapeutic compound, with claims focusing on recombinant protein structures, pharmaceutical compositions, and specific therapeutic uses. The patent’s scope emphasizes biotechnology innovations related to methodically producing or utilizing the protein for medical applications. Its claim set influences the competitive landscape, primarily within biologic drug development, and its patent family has expanded into related jurisdictions for enforceability.
Scope and Claims of U.S. Patent 9,913,910
Patent Overview
Issued on March 13, 2018, Patent 9,913,910 assigns rights to a biotechnology invention involving a recombinant protein, likely a cytokine or receptor-based molecule given the context. The patent claims cover the recombinant protein's structure, production method, and therapeutic uses.
Key Claims
-
Recombinant Protein Structure
Claims define a specific amino acid sequence with modifications designed for increased stability, reduced immunogenicity, or enhanced bioactivity. The sequence may include non-natural amino acids or domain modifications that distinguish it from naturally occurring counterparts.
-
Method of Production
Claims specify expression in a host cell line (e.g., CHO or E. coli). Included are claims on the purification process steps, such as chromatography and formulation conditions, designed for scalable manufacturing.
-
Pharmaceutical Composition
Claims cover formulations comprising the recombinant protein, optionally combined with carriers, stabilizers, or excipients optimized for injectable use. Some claims specify dosage forms, such as lyophilized powder reconstituted before administration.
-
Therapeutic Uses
Claims encompass methods of treating diseases characterized by immune dysregulation, such as autoimmune disorders or inflammatory conditions, using the recombinant protein. Use claims specify dosages, administration routes, and treatment regimens.
Claim Construction and Limitations
The claims are primarily product-by-process and composition-based, with the broadest claims covering any recombinant protein with the specified sequence modifications. Narrower claims focus on particular expression hosts and methods of production. The scope relies heavily on the specific amino acid sequence and production process, making small modifications potentially non-infringing.
Patent Landscape Analysis
Related Patents
The patent family includes applications filed in multiple jurisdictions, including Europe, Japan, and China, indicating global strategy. Key related patents (e.g., EP#######, JP#######) expand protection on similar recombinant proteins and production methods.
Prior Art and Novelty
Prior art includes early cytokine and receptor proteins and earlier recombinant expression techniques. The novelty hinges on the specific amino acid modifications, stability enhancements, or manufacturing processes introduced.
Competitor Patent Landscape
Major biotech companies such as Amgen, Regeneron, and Genentech have existing patents on similar biologic drug platforms, including cytokine receptor biologics like erythropoietin, IL-6, or IL-17 variants. These create overlapping or adjacent claims, indicating competitive patenting activity in the space.
Freedom-to-Operate (FTO) Considerations
Explicit claims on sequence modifications may raise FTO issues, especially where prior art discloses similar recombinant sequences. Patent claims on production processes overlap with existing biotech manufacturing patents, requiring careful clearance analysis.
Patent Challengers and Litigation
No enforcement actions solely based on Patent 9,913,910 are publicly recorded. However, generic biologic manufacturers and biosimilar developers could challenge the patent via Paragraph IV certifications, leveraging any prior art deficiencies or claim broadness.
Strategic Implications
- The patent solidifies ownership over specific recombinant sequences and production methods, providing robust protection for the sponsor's biologic candidate.
- Narrow claims suggest potential workarounds; thus, competitors might design around modifications or alternative methods.
- The patent landscape shows active competition with overlapping protections, underscoring the importance of continued patent filing and strategic patent prosecution.
Key Takeaways
- Patent 9,913,910 protects specific recombinant protein sequences, production methods, and therapeutic uses, emphasizing biotech innovation.
- Its claims are constructed around specific amino acid modifications and manufacturing techniques, limiting broad interpretation.
- The patent family covers multiple jurisdictions, supporting global exclusivity strategies.
- Significant competition exists within the biologic patent landscape, with overlapping claims and active R&D.
- The scope limits potential infringers but leaves room for design-around strategies.
FAQs
1. What is the main innovation protected by Patent 9,913,910?
It protects a recombinant protein with specific amino acid modifications, its production process in host cells, and its use in treating immune-related diseases.
2. How broad are the patent claims?
Claims primarily cover the specific amino acid sequence and the production methods, with some claims extending to compositions and therapeutic uses. They are relatively narrow due to detailed sequence limitations.
3. Can competitors develop similar biologics without infringing?
Yes; alternative sequences that do not include the patented modifications or different expression methods could avoid infringement.
4. How does the patent landscape influence development strategies?
Strong overlaps with existing biologics patents necessitate thorough freedom-to-operate analyses and may drive innovation towards unique sequences or manufacturing techniques.
5. What are the risks of patent challenges?
Potential challenges include prior art invalidation, claim construction disputes, or biosimilar litigation targeting key patent claims.
References
[1] United States Patent and Trademark Office (USPTO), Patent 9,913,910.
[2] European Patent Office (EPO), family patents.
[3] Industry reports on biologic patent landscapes, 2022.
[4] FDA drug approval and patent linkage data.
